08:30 am – 08:40 am

Abstract 1: Molecular profiling in ovarian cancer: impact on treatment selection

08:40 am – 08:50 am

Abstract 2: AI-driven imaging in ovarian masses (O-RADS 2026 update)

08:50 am – 09:00 am

Abstract 3: Novel biomarkers in platinum-resistant ovarian cancer

09:00 am – 09:10 am

Abstract 4: Real-world outcomes of PARP inhibitor maintenance

09:10 am – 09:20 am

Abstract 5: Fertility preservation in borderline ovarian tumors

09:20 am – 09:40 am

Discussion (Q&A)

10:00 am – 10:15 am

Break

10:15 am – 10:45 am 

Satellite Symposium

10:45 am – 01:00 pm

 prayer & Lunch Break

01:00 pm – 01:20 pm

Borderline ovarian tumors: evolving concepts in 2026

01:20 pm – 01:40 pm

PDS vs. IDS: updated NCCN guidelines 2026

01:40 pm – 02:00 pm

Management of low-grade serous ovarian cancer: new therapeutic strategies

02:20 pm – 02:50 pm

Satellite Symposium

03:05 pm – 03:35 pm

Satellite Symposium

03:35 pm – 04:15 pm

Rare ovarian cancers: updates in immunotherapy and targeted agents

04:15 pm – 04:30 pm

Discussion (Q&A)

08:00 am – 08:30 am

Abstracts (Endometrial cancer case presentations)

08:30 am – 08:50 am

Discussion (Q&A)

09:25 am – 09:55 am

Satellite Symposium

09:55 am – 10:15 am

Robotic surgery in EC: SLNB vs. para-aortic dissection

10:15 am – 10:35 am

Adjuvant therapy in stage III EC: NCCN 2026 changes

10:35 am – 10:55 am

What’s next after IO + chemotherapy in advanced EC

11:15 am – 11:30 am

Discussion (Q&A)

11:30 am – 12:00 pm

Satellite Symposium

12:00 pm – 02:00 pm

Prayer & Lunch Break

02:00 pm – 02:20 pm

Radiotherapy in intermediate/high-risk localized cervix cancer

02:20 pm – 02:40 pm

Keynote: A18 vs. Interlace – what to choose in 2026?

02:40 pm – 03:00 pm

Advances in brachytherapy and image-guided techniques

03:00 pm – 03:30 pm

Satellite Symposium

03:30 pm – 03:50 pm

Future directions in later-line cervix cancer therapy

04:10 pm – 04:30 pm

Closing Remarks